We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-6.76%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.35B
AUM Growth
-$253M
Cap. Flow
-$52M
Cap. Flow %
-2.22%
Top 10 Hldgs %
44.73%
Holding
154
New
14
Increased
27
Reduced
18
Closed
11

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$16.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$12.7M
3
JNJ icon
Johnson & Johnson
JNJ
+$12.2M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$11M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$10.1M

Top Sells

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$27.4M
2
A icon
Agilent Technologies
A
+$21.7M
3
CPHD
Cepheid Inc
CPHD
+$17.6M
4
LLY icon
Eli Lilly
LLY
+$16.4M
5
UNH icon
UnitedHealth
UNH
+$12.7M

Sector Composition

Rank Sector Weight
1 Healthcare 90.58%
2 Real Estate 3.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COR icon
26
Cencora
COR
$60.7B
$25.9M 1.1%
330,687
– –
CNC icon
27
Centene
CNC
$30.1B
$22.6M 0.96%
800,000
+287,000
+56% +$8.47M
MOH icon
28
Molina Healthcare
MOH
$10.2B
$21.8M 0.93%
402,541
– –
TMO icon
29
Thermo Fisher Scientific
TMO
$214B
$19.9M 0.85%
141,120
+54,725
+63% +$8.07M
NVS icon
30
Novartis
NVS
$301B
$18.1M 0.77%
277,661
– –
UHS icon
31
Universal Health Services
UHS
$9.88B
$15.6M 0.67%
146,780
+12,100
+9% +$1.43M
IDXX icon
32
Idexx Laboratories
IDXX
$44.1B
$15.5M 0.66%
132,352
– –
IBB icon
33
iShares Biotechnology ETF
IBB
$9.52B
$15.3M 0.65%
173,010
– –
NBIX icon
34
Neurocrine Biosciences
NBIX
$18.7B
$15.2M 0.65%
391,869
-264,753
-40% -$12M
ENDP
35
DELISTED
Endo International plc
ENDP
$15.1M 0.64%
914,548
– –
OHI icon
36
Omega Healthcare
OHI
$15B
$14.3M 0.61%
458,616
+45,500
+11% +$1.4M
HCA icon
37
HCA Healthcare
HCA
$85.7B
$14.1M 0.6%
190,232
+94,548
+99% +$7.08M
GSK icon
38
GSK
GSK
$104B
$13.8M 0.59%
287,200
– –
SBRA icon
39
Sabra Healthcare REIT
SBRA
$5.38B
$13.5M 0.57%
550,990
+94,800
+21% +$2.17M
UTHR icon
40
United Therapeutics
UTHR
$26.2B
$13.4M 0.57%
93,100
– –
SRPT icon
41
Sarepta Therapeutics
SRPT
$1.64B
$12.8M 0.54%
466,300
+252,200
+118% +$10.1M
AZN icon
42
AstraZeneca
AZN
$266B
$12.7M 0.54%
231,900
– –
MPT
43
Medical Properties Trust
MPT
$2.81B
$12.4M 0.53%
1,007,717
+168,500
+20% +$2.18M
SNY icon
44
Sanofi
SNY
$103B
$12.3M 0.53%
305,000
– –
DHC
45
Diversified Healthcare Trust
DHC
$2.17B
$12.2M 0.52%
646,554
+71,500
+12% +$1.39M
WELL.PRI
46
DELISTED
Welltower Inc.
WELL.PRI
$12M 0.51%
200,000
– –
PRTK
47
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$11.7M 0.5%
762,581
– –
CI icon
48
Cigna
CI
$76.1B
$11.5M 0.49%
86,400
– –
VTR icon
49
Ventas
VTR
$44.7B
$11M 0.47%
175,991
+23,500
+15% +$1.49M
CAH icon
50
Cardinal Health
CAH
$53.2B
$11M 0.47%
152,500
– –
1
2
3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2016 Portfolio in Review

As of Q4 2016, Tekla Capital Management held 154 positions worth $2.35B, down 9.7% from $2.6B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Tekla Capital Management's Q4 2016 filing shows 14 new, 27 increased, 18 reduced and 11 closed positions. Its largest new stake was State Street SPDR S&P Biotech ETF: 179,000 shares worth $10.6M. The largest sale was Alkermes, an estimated $27.4M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 92% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q4 2016 buy was State Street SPDR S&P Biotech ETF: 179,000 shares worth $10.6M.
  • Tekla Capital Management added most to Biogen in Q4 2016, an estimated $16.4M increase.
  • Tekla Capital Management's biggest Q4 2016 reduction was Eli Lilly, cutting an estimated $16.4M.
  • Tekla Capital Management fully exited Alkermes in Q4 2016, selling an estimated $27.4M.
  • Tekla Capital Management's ten largest holdings make up 45% of its $2.35B portfolio in Q4 2016.
  • Tekla Capital Management opened 14 new positions and closed 11 in Q4 2016.
  • Tekla Capital Management's portfolio value fell 9.7% quarter-over-quarter to $2.35B.

Based on Tekla Capital Management's 13F filing for Q4 2016, filed 13 Feb 2017.